Q-Line Biotech Limited

ANNEXURE – A

RESTATED CONSOLIDATED STATEMENT OF SHARE CAPITAL, RESERVES AND SURPLUS

(Amt. in Rs. Lakhs, Except Share Data)

<table><thead><tr><th rowspan="2">Particulars</th><th colspan="3">As at</th></tr><tr><th>31-03-2025</th><th>31-03-2024</th><th>31-03-2023</th></tr></thead><tbody><tr><td><strong>Share Capital</strong></td><td></td><td></td><td></td></tr><tr><td><strong>Authorised Share Capital</strong></td><td></td><td></td><td></td></tr><tr><td>No of Equity shares of face value of Rs.10/- each</td><td>40,00,000</td><td>40,00,000</td><td>40,00,000</td></tr><tr><td>Equity Share Capital of face value of Rs.10/- each</td><td>400.00</td><td>400.00</td><td>400.00</td></tr><tr><td><strong>Issued, Subscribed and Paid up Share Capital</strong></td><td></td><td></td><td></td></tr><tr><td>No of Equity Shares of face value of Rs. 10/- each fully paid up</td><td>15,75,000</td><td>15,75,000</td><td>15,75,000</td></tr><tr><td>Equity Share Capital of Face value of Rs 10/- each</td><td>157.50</td><td>157.50</td><td>157.50</td></tr><tr><td><strong>Total</strong></td><td><strong>157.50</strong></td><td><strong>157.50</strong></td><td><strong>157.50</strong></td></tr><tr><td><strong>Reserves and Surplus</strong></td><td></td><td></td><td></td></tr><tr><td><strong>(A) Surplus in Profit and Loss account</strong></td><td></td><td></td><td></td></tr><tr><td>Opening Balance as on period/year ended</td><td>15,893.89</td><td>12,448.97</td><td>9,239.26</td></tr><tr><td>Profit for the Year</td><td>2,813.09</td><td>3,444.92</td><td>3,209.71</td></tr><tr><td>Closing Balance as on period/year ended</td><td><strong>18,706.98</strong></td><td><strong>15,893.89</strong></td><td><strong>12,448.97</strong></td></tr><tr><td><strong>(B) Securities Premium</strong></td><td></td><td></td><td></td></tr><tr><td>Balance as per last financial statement</td><td><strong>130.05</strong></td><td><strong>130.05</strong></td><td><strong>130.05</strong></td></tr><tr><td>Add:- Issue of Equity shares premium of Rs. 407/- @15000 Shares</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Less: Issue of Bonus Shares</td><td>-</td><td>-</td><td>-</td></tr><tr><td><strong>Closing Balance</strong></td><td><strong>130.05</strong></td><td><strong>130.05</strong></td><td><strong>130.05</strong></td></tr><tr><td><strong>Total Reserve & Surplus (A+B)</strong></td><td><strong>18,837.03</strong></td><td><strong>16,023.94</strong></td><td><strong>12,579.02</strong></td></tr><tr><td>Less:- Equity attributable to non-controlling interest(Q-Line Innovation Private Limited)</td><td>-</td><td>-</td><td>-</td></tr><tr><td><strong>Total Reserve & Surplus after adjusting of Non Controlling Interest</strong></td><td><strong>18,837.03</strong></td><td><strong>16,023.94</strong></td><td><strong>12,579.02</strong></td></tr></tbody></table>

1. Terms/rights attached to equity shares:

(i) The company has only one class of equity shares having a par value of 10 per share. Each holder of equity shares is entitled to one vote per share.

(ii) In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

2. The figures disclosed above are based on the restated summary statement of assets and liabilities of the Company.

3. Company does not have any Revaluation Reserve.

4. There are no calls unpaid by the Directors or officers of the Company.

5. The company issued 1,41,75,000 Equity shares as Bonus to the approval of the Extra Ordinary General Meeting held on 28th August 2025 to existing shareholder in the ratio of 9:1.

6. Aggregate number of shares issued for consideration other than cash and shares bought back during the period of five years immediately preceding the year end:

(i) Shares allotted as fully paid pursuant to contract(s) without payment being received in cash during the financial year 2019-20 to 2023-24:-NIL

(ii) Shares issued in aggregate number and class of shares allotted by way of bonus shares during the financial year 2019-20 to 2023-24:- NIL

(iii) Shares bought back during the financial year 2019-20 to 2023-24:- NIL

(iv) Shares issued under employee stock option plan (ESOP) during the financial year 2019-20 to 2023-24:- NIL

(v) Shares reserved for issue under options:- NIL

7. No Shares in respect of each class in the company held by its holding company or its ultimate holding company including shares held by or by subsidiaries or associates of the holding company or the ultimate holding company in aggregate.

8. The Authorised Share Capital of the Company was increased from ₹400 Lakhs divided into 40,00,000 no. of equity shares of ₹ 10 each to ₹ 2500 Lakhs divided into 250,00,000 no. of equity shares of ₹ 10 each, purusnat to the approval of the Extra Ordinary General meeting held on 01st August, 2025.

9. There has been no buy back of share in company from the period of incorporation.

200